<DOC>
	<DOCNO>NCT00212849</DOCNO>
	<brief_summary>The purpose study measure outcomes patient articular cartilage lesion patellofemoral joint treat Autologous Chondrocyte Implantation .</brief_summary>
	<brief_title>Autologous Chondrocyte Implantation Patellofemoral Joint</brief_title>
	<detailed_description>Cartilage restoration , general , relatively new option treatment articular cartilage lesion primarily knee . In initial autologous culture chondrocyte transplantation ( ACT , others implantation , thus ACI ) report Peterson et . al. , result femoral lesion favorable , 5 7 patellofemoral treatment poor . In United States , expedite FDA approval base result exclude patella . As result , United States , difficult evaluate use ACI patellofemoral joint light exclusion “ label ” use many governmental private insurance program . Nevertheless , grow body knowledge accumulate outside United States use ACI patella viable option soon similar finding publish US Minas et . al . ( accepted publication )</detailed_description>
	<criteria>Carticel Implantation patella and/or trochlear lesion . Patients reach twoyear followup date . All patient include sequential order . Patients microfracture knee joint time Carticel Implantation . Patients implantable lesion patella trochlea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>Articular Cartilage Lesions</keyword>
	<keyword>Patellar lesion</keyword>
	<keyword>Trochlear lesion</keyword>
	<keyword>Patellofemoral joint</keyword>
	<keyword>Carticel</keyword>
	<keyword>Autologous Chondrocyte Implantation</keyword>
</DOC>